New Skin Cancer Treatments 2022

What is Skin Cancer?

Skin cancer is the most common form of cancer. It forms when cells in the epidermis, the outermost layer of the skin, start to grow out of control. Skin cancer is caused by unrepaired DNA damage that triggers mutations, which leads to skin cells to grow and divide rapidly. Skin cancer is mostly found on skin areas typically exposed to the sun, such as the face, shoulders, hands, arms and legs. Every type of skin cancer appears differently. The main types of skin cancer are basal cell carcinoma (BCC), squamous cell carcinoma (SCC), melanoma and Merkel cell carcinoma (MCC). BCC is the most common type and SCC the second most common type of skin cancer. When left untreated, skin cancer can spread to other parts of the body (metastasize) or become unable to be removed by surgery (unresectable).¹

Can Skin Cancer be cured?

When detected early, most skin cancer can be treated and cured. Some skin cancer can be removed or destroyed with local treatment methods. Small tumors can usually be cured with these treatments. However, larger tumors are more difficult to treat, and cancers that are fast-growing have a higher risk of coming back.²

How to treat Skin Cancer?

Fortunately, most skin cancers and pre-skin-cancers can be cured with relatively minor surgery or other types of local treatments. The different types of skin cancer are treated in different ways. Especially when the cancers are found and treated by a skin cancer specialist at an early stage, they can be removed or destroyed with local treatments. Surgery is the most common treatment for skin cancer. The skin cancer doctor cuts away the spot. If this is not possible, or if the cancer has spread (metastasized), there are various other treatments for skin cancer. This includes skin cancer creams and ointments and skin cancer medications.

What are the newest Skin Cancer Treatments?

There are several approved Skin Cancer treatments options. Here are some of them:

Libtayo (cemiplimab) is a programmed death receptor-1 (PD-1) blocking antibody used for the treatment of advanced cutaneous SCC and advanced BCC. It is also approved for advanced non-small cell lung cancer (NSCLC).

Libtayo (cemiplimab) was approved by:

• Food and Drug Administration (FDA), US:
• September 2018 for advanced cutaneous SCC
• February 9, 2021 for advanced BCC
• European Medical Agency (EMA), Europe:
• June 28, 2019 for advanced BCC
• Health Canada, Canada:
• April 10, 2019 for advanced BCC

Braftovi (encorafenib) is a kinase inhibitor indicated for the treatment of certain cancers with a mutation (change) in their genes called 'BRAF V600'. It is indicated in combination with Mektovi (binimetinib) to treat people with metastatic unresectable melanoma that has a BRAF V600E or V600K mutation. It is also used in combination with cetuximab, for the treatment of adults with advanced colorectal cancer (cancer of the large bowel or rectum).

Braftovi (encorafenib) was approved for the treatment of unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation by:

• Food and Drug Administration (FDA), USA on June 27, 2018.
• European Medicines Agency (EMA) on September 20, 2018.

Mektovi (binimetinib) is a kinase inhibitor indicated for the treatment of patients with melanoma that has a specific mutation (change) in their genes called 'BRAF V600'. It is taken together with Braftovi (encorafenib), another kinase inhibitor.

Mektovi (binimetinib) was approved for the treatment of people with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation by:

• Food and Drug Administration (FDA), USA on June 27, 2018.
• European Medicines Agency (EMA) on September 20, 2018.

If you are trying to access Skin Cancer drugs that are approved outside of your country of residence, we might be able to help you access it with the support of your treating doctor. You can read more about the medicines we can help you and your doctor access and about their price below:

Libtayo (cemiplimab)

Braftovi (encorafenib)

Mektovi (binimetinib)

View all

Why access and buy treatments for Skin Cancer with everyone.org?

everyone.org is registered in The Hague with the Dutch Ministry of Health as a pharmaceutical wholesale distributor (registration number 16258 G). We have helped patients from over 85 countries to access thousands of medicines that are not yet approved in their home country, including patients with Skin Cancer. With a prescription from your treating doctor, you can count on our expert team to safely and legally guide you to access Skin Cancer drugs. If you or someone you know are looking to access a medicine that is not yet approved where you live, we will support you. Contact us for more information.

References:

1. About Skin Cancer
2. Treatment
3. Libtayo (cemiplimab) - Thesocialmedwork.com
4. Libtayo product information sheet [PDF]
5. Braftovi (encorafenib) - Thesocialmedwork.com
6. Braftovi product information sheet [PDF]
7. Mektovi (binimetinib) - Thesocialmedwork.com
8. Mektovi product information sheet [PDF]

Disclaimer: This article is not meant to influence or impact the care provided by your treating physician. Please do not make changes to your treatment without first consulting your healthcare provider. This article is not intended to diagnose or treat illness or to influence treatment decisions. everyone.org is as diligent as possible in compiling and updating the information on this page. However, everyone.org does not guarantee the correctness and completeness of the information provided on this page.